NEWS RELEASE Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets Nijmegen, the Netherlands, Berlin, Germany – 27 July ...

Byondis operates from its headquarters in Nijmegen in the Netherlands, with over 350 highly qualified employees working in state-of-the art research and development and GMP manufacturing facilities.

NIJMEGEN, The Netherlands, November 19, 2024--Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the ...

Nijmegen, the Netherlands – 7 October 2021 – Byondis BV, an independent, clinical stage biopharmaceutical company creating precision medicines, annou Tuesday, 02 January 2024 12:17 GMT عربي ...

NIJMEGEN, Netherlands , June 8, 2021 /PRNewswire/ -- Byondis B.V. today announced positive topline results from the Phase III TULIP® study, a multi-center, open-label, randomized clinical ...

NIJMEGEN, The Netherlands, August 19, 2020 / B3C newswire / --Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) is pleased to announce the appointment of Robbert Van Heekeren as chief financial ...

NIJMEGEN, Netherlands, July 15, 2021 /PRNewswire/ -- Byondis B.V. today announced the appointment of Timo K. van den Berg, Ph.D., as senior director, Immuno-Oncology (IO) Research and Development ...

SYD985 Marketing Authorization Application Soon to Be Submitted to the EMA NIJMEGEN, Netherlands and WEDEL, Germany, May 3, 2022 /PRNewswire/ -- Byondis B.V., an independent, Dutch clinical ...

NIJMENGEN , the Netherlands and BERLIN, July 27, 2021 /PRNewswire/ -- Byondis B.V., an independent, clinical stage biopharmaceutical company creating precision medicines, and Glycotope, a ...

Byondis B.V., an independent ... has a dedicated team of more than 300 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.

NEWS RELEASE Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets Nijmegen, the Netherlands, Berlin, Germany – 27 July 2021 – ...